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Abstract
Background: Osteoblasts are considered to primarily arise from osseous progenitors within the
periosteum or bone marrow. We have speculated that cells from local soft tissues may also take
on an osteogenic phenotype. Myoblasts are known to adopt a bone gene program upon treatment
with the osteogenic bone morphogenetic proteins (BMP-2,-4,-6,-7,-9), but their osteogenic
capacity relative to other progenitor types is unclear. We further hypothesized that the sensitivity
of cells to BMP-2 would correlate with BMP receptor expression.
Methods: We directly compared the BMP-2 sensitivity of myoblastic murine cell lines and primary
cells with osteoprogenitors from osseous tissues and fibroblasts. Fibroblasts forced to undergo
myogenic conversion by transduction with a MyoD-expressing lentiviral vector (LV-MyoD) were
also examined. Outcome measures included alkaline phosphatase expression, matrix
mineralization, and expression of osteogenic genes (alkaline phosphatase, osteocalcin and  bone
morphogenetic protein receptor-1A) as measured by quantitative PCR.
Results:  BMP-2 induced a rapid and robust osteogenic response in myoblasts and
osteoprogenitors, but not in fibroblasts. Myoblasts and osteoprogenitors grown in osteogenic
media rapidly upregulated Bmpr-1a expression. Chronic BMP-2 treatment resulted in peak Bmpr-1a
expression at day 6 before declining, suggestive of a negative feedback mechanism. In contrast,
fibroblasts expressed low levels of Bmpr-1a that was only weakly up-regulated by BMP-2 treatment.
Bioinformatics analysis confirmed the presence of myogenic responsive elements in the proximal
promoter region of human and murine BMPR-1A/Bmpr-1a. Forced myogenic gene expression in
fibroblasts was associated with a significant increase in Bmpr-1a  expression and a synergistic
increase in the osteogenic response to BMP-2.
Conclusion: These data demonstrate the osteogenic sensitivity of muscle progenitors and provide
a mechanistic insight into the variable response of different cell lineages to BMP-2.
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Background
The conventional view of bone cell differentiation is that
pluripotent or multi-potent stem cells commit to an oste-
oprogenitor lineage and then undergo a smooth, consist-
ent, and well defined transition to produce differentiated
osteoblasts. Osteoprogenitors are considered to be com-
mitted to an osteochondral lineage once they express the
key transcription factor Runx2/Cbfa1  [1]. As osteogenic
differentiation proceeds, other markers of bone differenti-
ation such as osterix, alkaline phosphatase (AP), bone sialo-
protein, and osteocalcin (OCN) are sequentially expressed.
The processes of osteoprogenitor commitment and oste-
oblast differentiation are both facilitated by members of
the bone morphogenetic protein (BMP) protein family
[2]. BMP homodimers and heterodimers bind to BMP
receptors (BMPRs) on the cell surface that can transduce
the concentrations of extracellular BMPs into specific
changes in gene expression [3]. BMPR-IA and BMPR-II are
reported to be ubiquitously expressed, whereas BMPR-IB
is tissue specific [4-6]. While the expression of BMPs in
bone development and repair are well described [7,8], the
potential for lineage-specific control of BMP signaling by
regulating BMPR expression levels has not been explored
in detail.
Committed osteoprogenitors are traditionally considered
to arise from progenitors within the periosteum (a thin
cellular layer covering bone surfaces) and within the bone
marrow. In the bone marrow, the bone marrow stromal
cells (BMSCs) encompass a heterogeneous population of
highly plastic cells that not only support the haematopoi-
etic progenitors, but also contribute to endosteal bone
formation [9]. MSCs are multipotent and can be stimu-
lated to differentiate into cells of the osteoblastic, chon-
drogenic, myogenic, and adipogenic lineages [10]. By
necessity, BMSCs must maintain themselves in a relatively
undifferentiated state within the bone compartment.
Although BMSCs generally remain in the marrow space,
osteoprogenitors likely to have originated from the mar-
row have also been detected in the circulation [11], and it
has been suggested that these circulating cells may also
contribute to bone formation and repair [12].
We have speculated that other cell types arising from the
soft tissues adjacent to bone may also be able to contrib-
ute to bone formation and repair [13]. This would pre-
sumably occur via transdifferentiation, a process where
non-osseous progenitors could be reprogrammed to an
osteogenic lineage [14]. Muscle progenitors are an appeal-
ing candidate for osteogenic transdifferentiation, as cul-
tured myoblasts readily adopt a bone cell phenotype
upon treatment with the osteogenic BMPs [15,16].
There are multiple indirect observations that suggest stem
cells situated within muscle can participate in bone for-
mation and repair. Muscle is found adjacent to most
bones and can be exposed to bone signals upon injury.
Disease states can also alter bone signaling resulting in
ossification within muscle tissue, such as in myositis ossifi-
cans or in the genetic disease fibrodysplasia ossificans pro-
gressiva (FOP)[17,18]. Moreover, recent evidence would
suggest that inhibition of BMP type 1 receptor signaling
may be effective in the treatment of FOP [19]. During
recalcitrant bone repair, new bone formation is most
commonly seen at the muscle-bone interface. Although
this implies the presence of osteoprogenitor cells within
muscle, it is unclear whether the cells that contribute to
the bone healing process arise from muscle progenitors
(satellite cells), are associated with the vasculature (peri-
cytes) [20], exist as a small sub-population of multipotent
stem cells [21,22], or migrate from the circulation [11].
Numerous in vitro and in vivo experiments have induced
osteogenesis in skeletal myoblasts [15,16,23-29] how-
ever, their sensitivity to osteogenic signals relative to other
cell types remains unclear. In a paper by Komaki and col-
leagues, forced expression of the muscle master transcrip-
tion factor MyoD in mesenchymal C3H10T1/2
progenitors led to an enhancement of BMP-7 induced
osteogenesis [30]. While MyoD has been shown to stimu-
late the pro-osteogenic transcription factor Osx [31],
forced MyoD expression alone is insufficient to promote
osteogenic differentiation. We therefore hypothesized
that MyoD may potentiate BMP signaling via BMP recep-
tor expression. Myoblasts robustly express BMPR-IA and
BMPRII [32], and this may underlie their sensitivity to
bone signals [33].
In this study we report a detailed comparison of the
response of different mesenchymal progenitors to BMP
treatment. Specifically, pre-osteoblasts, BMSCs, skeletal
myoblasts, and fibroblasts were examined in a head-to-
head fashion, including a combination of cell lines and
primary murine cells. This study also aimed to address
whether the capacity of progenitors for osteogenic conver-
sion correlates with the expression of BMPRs, and if
forced myogenesis could affect BMPR expression and
BMP sensitivity in fibroblasts.
Methods
Cell culture
C2C12 myoblasts were cultured in DMEM containing
20% FBS while NIH/3T3 fibroblasts were cultured in
DMEM containing 10% FBS. MC3T3-E1 pre-osteoblasts
were grown in α-MEM containing 10% FBS.
Primary murine cells were obtained from 8–12 week old
C57BL6/J mice in a study approved by the CHW animalBMC Musculoskeletal Disorders 2009, 10:51 http://www.biomedcentral.com/1471-2474/10/51
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ethics committee. Primary myoblasts were isolated from
mouse hindlimb muscles and enzymatically digested with
0.25% pronase (Merck Sharp & Dohme, Granville, NSW,
Australia) for 1 hr at 37°C. Digestion was terminated by
the addition of DMEM containing 10% horse serum (Inv-
itrogen, Carlsbad, CA, USA). Isolated cells were sequen-
tially filtered through a 100 μm and 40 μm cell strainers
and purified based on a previously published pre-plating
technique [34]. Primary myoblasts were cultured in
DMEM containing 20% FBS. Primary fibroblasts were
obtained by a similar digestion process from fascia adja-
cent to skeletal muscle and grown in DMEM containing
10% FBS. Primary BMSCs were selected to represent a less-
differentiated mesenchymal progenitor population (as
opposed to neonatal calvarial osteoblasts, which exhibit a
more mature osteoblastic phenotype). BMSCs were iso-
lated from mouse femurs by flushing the bone marrow
from the medullary canal with DMEM using a 21 gauge
needle. After 3 days of culture in DMEM containing 10%
FBS, non-adherent cells were removed by washing and
aspiration. Primary cells and cell lines were cultured with
antibiotics consisting of 100 unit/ml penicillin and 0.1
mg/ml streptomycin and grown in humidified chambers
at 37°C with 5% CO2.
Inducing osteogenic differentiation
Cells were plated in triplicate at a density of 1 × 104 cells/
well in 48-well collagen-coated plates and osteogenic dif-
ferentiation was induced by culturing cells in osteogenic
media (MC3T3-E1 growth media supplemented with 50
μg/ml ascorbic acid and 10 mM β-glycerophosphate).
Cells were grown either with 0 or 200 ng/ml BMP-2
(Kamiya Biotech, Thousand Oaks, CA, USA), with media
changes every second day.
Cell viability and alkaline phosphatase (AP) activity assay
Cellular viability was determined using the CellTitre 96
Aqueous One Solution Cell Proliferation Assay kit
(Promega, Madison, WI, USA) according to the manufac-
turer's instructions. AP activity in cells was detected using
p-nitrophenylphosphate (pNPP) (Sigma-Aldrich, St Louis,
MO, USA) as the substrate. Cells were fixed with 4% para-
formaldehyde (PFA) for 15 min and washed with AP wash
buffer (0.1 M NaCO3 pH 10, 1 mM MgCl2). Cells were
then incubated with 10 mM pNPP and the reaction left to
incubate for 20 min at 37°C. Absorbance was read at 405
nm and the enzyme activity was normalized to cell
number obtained from viability assays. All samples were
assayed in triplicate. Results are representative of a mini-
mum of two independent experiments.
Histochemical staining
Mineralization of calcium deposits was assessed by Ali-
zarin Red S staining. Cultures were fixed with 4% PFA for
15 min at room temperature and then stained with Ali-
zarin Red S for 10 min (40 mM, pH 4.2). Non-specific
staining was removed by several washes with distilled
water.
RNA extraction, cDNA preparation, and real-time 
quantitative PCR (qPCR)
Total cellular RNA was extracted from cells grown in 6-
well plates using TRIZOL reagent (Invitrogen) as per the
manufacturer's instructions. cDNA was then reverse-tran-
scribed from equivalent amounts of total RNA using
Superscript III Reverse Transcriptase (Invitrogen). The
PCR primer sequences used for amplification are listed in
Table 1. All samples were amplified using the SYBR Green
PCR reagent kit (Integrated Sciences, Chatswood, NSW,
Australia) according to the manufacturer's protocol. PCR
was performed on the Rotor-Gene 3000 (Corbett Life Sci-
ence, Sydney, NSW, Australia).
All samples were initially denatured at 94°C for 2 min fol-
lowed by 40 amplification cycles for Ap, Ocn, and MyoD
(95°C for 15 s, 60°C for 60 s, and 72°C for 60 s); 55
amplification cycles for Bmpr-1a, and Bmpr-2 (94°C for 60
s, 55°C for 60 s, and 72°C for 60 s); 35 cycles for Gapdh
(94°C for 30 s, 55°C for 60 s, and 72°C for 60 s) and
extension at 72°C for 60 s. PCR reactions were performed
in triplicates and normalized to the housekeeping gene
Gapdh, to control for cDNA loading. Data are presented as
mean fold induction (± SE).
BMPR promoter analysis
The procedure used to identify potential myogenic regula-
tory motifs was employed over a region encompassing 2
kb upstream of the BMPR1A transcription start site. This
region of interest was identified and extracted in both
mouse and human using the UCSC genome browser [35].
Table 1: Oligonucleotide sequences for quantitative PCR (qPCR)
Target cDNA sequence Sense primer Anti-sense primer
MyoD 5'-CGGCTACCCAAGGTGGAGAT-3' 5'-ACCTTCGATGTAGCGGATGG-3'
Bmpr-1a 5'-ACATCAGATTACTGGGAGCC-3' 5'-TATAGCAAAGCAGCTGGAG-3'
Bmpr-2 5'-GTGCCCTGGCTGCTATGG-3' 5'-TGCCGCCTCCATCATGTT-3'
Gapdh 5'-GCCACCCAGAAGACTGTGGATGGC-3' 5'-CATGTAGGCCATGAGGTCCACCAC-3'
Ap 5'-GGGACTGGTACTCGGATAACGA-3' 5'-CTGATATGCGATGTCCTTGCA-3'
Ocn 5'-CGGCCCTGAGTCTGACAAA-3' 5'-GCCGGAGTCTGTTCACTACCTT-3'BMC Musculoskeletal Disorders 2009, 10:51 http://www.biomedcentral.com/1471-2474/10/51
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A position-specific scoring matrix tool, MatInspector [36],
was then used to locate putative binding sites for myo-
genic transcription factors MyoD, MEF2, MYF3, MYF5 and
Myogenin. Low confidence matches were filtered out,
retaining only those corresponding to a matrix similarity
score of greater than 0.9.
Forced myogenesis in NIH/3T3 fibroblasts
Lentivirus vectors expressing eGFP (LV-eGFP) or the myo-
genic transcription factor MyoD (LV-MyoD) under the
control of the cytomegalovirus (CMV) promoter were
generated using published methods [37]. NIH/3T3
fibroblasts were transduced at a multiplicity of infection
(MOI) of 50 in the presence of 8 μg/ml Polybrene (Sigma-
Aldrich) overnight. Fresh media was added 18–24 hours
following transduction and cells were cultured for a fur-
ther 2 days before cells were treated with osteogenic
media with 200 ng/ml BMP-2 for another 3 days. At the
end of the culture period, RNA samples were purified for
qPCR analysis.
Statistical analysis
Assays were conducted at least in triplicate. Values are pre-
sented as mean ± standard error (SE), and statistical com-
parisons were made using a two-tailed student's t-test. P
values <0.05 were considered statistically significant.
Results
BMP-2 stimulates osteogenesis in myoblastic but not 
fibroblastic cell lines
The C2C12 and NIH/3T3 cell lines were used to examine
the capacity of myoblasts and fibroblasts to undergo
BMP-induced osteogenic differentiation respectively. The
pre-osteoblastic MC3T3-E1 cell line is not only BMP-
responsive but readily undergoes osteogenic differentia-
tion in the absence of BMP treatment, and was used as a
positive control. Cells were cultured in osteogenic media
and treated cells received 200 ng/ml of BMP-2. Ap gene
expression, AP staining and AP activity assays were meas-
urements for early bone marker expression, while Ocn
gene expression and mineralized matrix staining were
used as indicators for mature bone differentiation.
The addition of BMP-2 increased Ap mRNA levels in both
MC3T3-E1 pre-osteoblasts and C2C12 myoblasts (Fig
1A–B). By day 9, Ap mRNA in BMP-2 treated MC3T3-E1
and C2C12 cells decreased to levels that were similar to
those of the untreated cells (Fig 1B). In contrast, NIH/3T3
cells continued to upregulate Ap  expression up to and
after 9 days in culture (Fig 1B). BMP-2 had no significant
effect on Ocn transcript levels early in culture (Fig 1C–D).
In all cell types, Ocn expression increased with prolonged
culturing. Notably, BMP-2 upregulated C2C12 Ap  and
Ocn mRNA to a level comparable to that of BMP-2 treated
MC3T3-E1 cells.
In MC3T3-E1 and C2C12 cells, the addition of BMP-2
increased AP activity early on (Fig 1E) and mineralized
matrix staining at late time points (Fig 1F). BMP-2 treat-
ment increased osteogenic markers in these cells in a dose-
dependent manner. This increase in myoblasts was
accompanied by a concomitant downregulation in myo-
genic expression as seen by immunofluorescent staining
for desmin and MyoD (data not shown). In contrast, the
NIH/3T3 fibroblasts showed negligible AP activity and
did not generate mineralized nodules over the same cul-
ture period. Furthermore, NIH/3T3 fibroblasts cells
acquired only sporadic AP positive cells after 18 days of
BMP-2 treatment and failed to generate a mineralized
matrix even after 24 days in culture (data not shown)
BMP-2 stimulates osteogenesis in primary cells from 
muscle tissue but not muscle fascia
Myoblastic cells capable of spontaneously differentiating
and fusing into myotubes were generated by a standard
method involving enzymatic digestion of mouse muscle
tissue [34]. This method generated cultures possessing
>80% desmin positive myoblasts capable of fusing into
multinucleated myotubes. Primary cells were also cul-
tured from muscle fascia. In contrast to the muscle-
derived cells, fascial cells developed a stellate morphology
and failed to express desmin (data not shown). As con-
trols, BMSCs, which are known to be osteocompetent,
were obtained by flushing the femoral marrow cavity and
removing non-adherent cells at 3 days after plating.
BMSCs endogenously expressed osteoblast-specific genes,
and these were further elevated when cells were cultured
with BMP-2 (Fig 2). Untreated primary myoblasts
expressed levels of Ap  and  Ocn  similar to those of
untreated BMSCs, which were upregulated with the addi-
tion of BMP-2. Elevated levels of Ap in primary myoblasts
persisted for 6 days and then gradually declined (Fig 2A–
B) such that Ap expression was below the level of detec-
tion by 18 days (data not shown). The decrease in early
bone markers was concomitant with an upregulation in
the late marker Ocn (Fig 2C–D). Patterns of Ap and Ocn
expression were comparable between BMP-treated pri-
mary myoblasts and BMSCs. Fascial fibroblasts treated
with BMP-2 expressed very low levels of bone-specific
mRNAs and no significant increase in Ap and Ocn tran-
scripts was observed.
BMP-2 induced robust AP expression (Fig 2E) and miner-
alization staining (Fig 2F) in primary myoblasts that were
superior even compared to cultured BMSCs. In contrast,
very few AP positive cells were seen in primary fibroblast
cultures treated with BMP-2 and no matrix mineralization
was observed. The addition of BMP-2 to primary myob-
lasts resulted in decreases in desmin and MyoD expres-BMC Musculoskeletal Disorders 2009, 10:51 http://www.biomedcentral.com/1471-2474/10/51
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The effect of BMP-2 on the osteogenic expression in cell lines Figure 1
The effect of BMP-2 on the osteogenic expression in cell lines. Osteogenic gene expression was examined in MC3T3-
E1 (dot-dash line), C2C12 (straight line) and NIH/3T3 (dotted line) cell lines using qPCR with the data normalized to the 
housekeeping gene Gapdh. Ap expression was measured as an early osteogenic marker in cells grown in the absence (A) or the 
presence (B) of BMP-2. Ocn gene expression was measured as a late osteogenic marker in cells cultured in the absence of 
BMP-2 (C) or with BMP-2 added (D). In addition, the dose- and cell-dependent effect of BMP-2 on AP activity after 6 days (E) 
and mineralized nodule formation after 12 days (F) was measured in all three cell lines. Scale bar = 100 μm.BMC Musculoskeletal Disorders 2009, 10:51 http://www.biomedcentral.com/1471-2474/10/51
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The effect of BMP-2 on the osteogenic expression in primary-derived cells Figure 2
The effect of BMP-2 on the osteogenic expression in primary-derived cells. Osteogenic gene expression was exam-
ined in primary BMSCs (dot-dashed line), primary myoblasts (straight line) and primary fibroblasts (dotted line) using qPCR and 
data normalized to the housekeeping gene Gapdh. Ap expression was measured as an early osteogenic marker in cells cultured 
in the absence (A) or the presence (B) of BMP-2. Ocn expression was measured as a late osteogenic marker in cells grown in 
the absence (C) or the presence (D) of BMP-2. In addition, dose- and cell-dependent effect of BMP-2 on AP activity after 6 
days (E) and mineralized nodule formation after 12 days (F) was measured in all three cell lines. Scale bar = 100 μm.BMC Musculoskeletal Disorders 2009, 10:51 http://www.biomedcentral.com/1471-2474/10/51
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sion, similar to that observed for C2C12 cells (data not
shown).
Bioinformatics analysis of the BMPR promoter regions
Based on the high relative BMP-responsiveness of myo-
genic cells, the upstream promoter regions of the BMPRs
were examined for myogenic regulatory elements. Analy-
sis was performed using MatInspector, a software package
that identifies transcriptional binding sites which uses
advanced filtering to generate high-quality matches. A
number of high-confidence myogenic factor binding sites
were identified in mouse and human Bmpr-1a/BMPR-1A
promoter regions. In the mouse, this corresponded to one
MyoD and two MEF2 sites, and in the human this corre-
sponded to three MyoD and two MEF2 sites (Fig 3). The
expected number of occurrences due to chance alone over
a 2 kb region was 0.26 and 0.06 for the MyoD and MEF2
motifs in both mouse and human, respectively. Thus the
observed number of occurrence(s) for each motif was
always greater than the expected species-specific occur-
rence value, denoting that sufficiently stringent criteria
were employed to identify putative transcription factor
binding sites. Several Smad-binding consensus sequences
were also detected (data not shown), indicating the
potential involvement of alternative non-myogenic regu-
latory elements.
Analysis of the murine Bmpr-1b and Bmpr-2 2 kb promoter
sequence identified a single MyoD site in each. Based on
the expected number of false positives, identification of
these sites was not sufficient to establish myogenic
responsiveness.
Osteogenic sensitivity correlates with Bmpr-1a expression
To further explore BMPR expression as a mechanism for
modulating osteogenic differentiation, gene expression
was examined in cell lines and primary cells. Bmpr-1a
expression was readily detectable by qPCR. Basal levels of
the Bmpr-1a gene in NIH/3T3 fibroblasts were found to be
significantly lower than in MC3T3-E1 pre-osteoblasts
(38% reduction, p = 0.02). No significant difference was
seen between C2C12 myoblasts and MC3T3-E1 cells.
Bmpr-1a expression was further upregulated in these lines
cultured in osteogenic media, either in the absence or
presence of BMP-2 (Fig 4A–B). Notably, C2C12 cells
treated with BMP-2 eventually down-regulated their
Bmpr-1a  expression by day 9; this was also evident in
MC3T3-E1 cells. In contrast, NIH/3T3 cells did not signif-
icantly upregulate their Bmpr-1a expression with BMP-2
treatment. In NIH/3T3 fibroblasts, Bmpr-1a was only sub-
stantively elevated after 21 days in culture (5.3-fold higher
p = 0.002 compared to day 0 cells) (data not shown). In
primary cell cultures, comparable results were observed
(Fig 4C–D).
Forced expression of MyoD in fibroblasts enhances Bmpr-
1a expression
Prior experiments indicated that Bmpr-1a  was robustly
expressed by myoblasts but not fibroblasts. To determine
whether myogenic factors were important for modulating
Bmpr-1a expression, we forced fibroblasts to differentiate
down the myogenic lineage using a MyoD-expressing len-
tiviral vector (LV-MyoD). To account for any adverse
effects on cell signaling mediated by lentiviral transduc-
tion, an equivalent eGFP lentiviral vector (LV-eGFP) was
included as a control. Viral transduction was efficient and
Analysis of the human and murine BMPR-1A/Bmpr-1a promoter region Figure 3
Analysis of the human and murine BMPR-1A/Bmpr-1a promoter region. Putative myogenic transcription factor bind-
ing sites were identified by MatInspector in human and murine BMPR-1A/Bmpr-1a promoter regions. Putative MEF2 and MyoD 
binding sites were predicted within a 2 kb region upstream from the BMPR-1A transcriptional start site; putative MEF2 and 
MyoD were also predicted in the corresponding 2 kb region upstream from the Bmpr1a transcriptional start site. The tran-
scriptional start site was inferred from Genbank entries NM_004329 (human) and NM_009758 (mouse). Low confidence and 
non-myogenic predictions are not shown.BMC Musculoskeletal Disorders 2009, 10:51 http://www.biomedcentral.com/1471-2474/10/51
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high levels of eGFP were detected in a majority (>70%) of
the cells 72 hrs post-transduction (data not shown). Crit-
ically, NIH/3T3 fibroblasts transduced with the LV-MyoD
construct fused and formed myotubes demonstrating suc-
cessful induction of a myogenic differentiation program
(Fig 5A). A 20–25 fold increase in MyoD expression was
also confirmed by qPCR (Fig 5B).
Three days after transduction, eGFP- and MyoD-express-
ing NIH/3T3 cells were cultured for an additional 3 days
in growth media or osteogenic differentiation media sup-
plemented with BMP-2. Analysis by qPCR revealed a 4.6
fold increase in Bmpr-1a expression in MyoD-expressing
NIH/3T3 cells without BMP-2 (p = 0.02) and a 6.9 fold
increase in MyoD-expressing NIH/3T3 cells treated with
Cellular response to BMP-2 correlates to theexpression levels of Bmpr-1a Figure 4
Cellular response to BMP-2 correlates to theexpression levels of Bmpr-1a. Bmpr-1a expression levels were examined 
using qPCR and normalized to the housekeeping gene Gapdh. Values were generated for cell lines grown in the absence of 
BMP-2 (A) or with BMP-2 added (B), and in mouse primary derived cells grown without (C) or with (D) BMP-2 treatment. 
Bmpr-1a expression increased over time when cells were grown in osteogenic media, and were even greater under BMP-2 
stimulation. The lowest Bmpr-1a levels were observed in NIH/3T3 cells and primary fibroblasts, which were previously shown 
to be the least sensitive to BMP-2 treatment.BMC Musculoskeletal Disorders 2009, 10:51 http://www.biomedcentral.com/1471-2474/10/51
Page 9 of 12
(page number not for citation purposes)
BMP-2 (p = 0.02) (Fig 5C). Ap expression was then meas-
ured as an indicator of osteogenesis. Ap  expression in
MyoD-transduced fibroblasts grown in growth media was
comparable to levels seen in non-transduced cells and LV-
eGFP transduced controls. However, when LV-MyoD
transduced fibroblasts were treated with BMP-2, Ap
expression was elevated 23 fold (p = 0.01) compared to
non-transduced controls (Fig 5D). Thus, forced myogene-
sis and exogenous BMP-2 treatment acted synergistically
in fibroblasts to upregulate Ap expression.
Discussion
This study represents a controlled head-to-head compari-
son of the responsiveness of different progenitor lineages
to BMP-2. While prior studies have illustrated that BMP-2
can induce an osteogenic phenotype in myogenic cells, we
Forced MyoD expression in NIH/3T3 fibroblasts increases Bmpr-1a expression Figure 5
Forced MyoD expression in NIH/3T3 fibroblasts increases Bmpr-1a expression. NIH/3T3 cells were transduced 
using LV-MyoD and LV-eGFP lentiviral vectors. Fibroblasts transduced with LV-MyoD developed an elongated morphology 
that resembled myotubes (A). Scale bar = 50 μm. Three days after the initial transduction, cells were cultured for a further 3 
days in the presence or the absence of BMP-2. Gene expression for MyoD (B), Bmpr-1a (C) and Ap (D) were measured using 
qPCR, relative to Gapdh. Comparative expression analysis was performed relative to non-transduced, untreated NIH/3T3 
fibroblasts. The majority of values were statistically significant (*p < 0.05, **p < 0.01), however, substantive changes in gene 
expression (>4-fold increase) were only observed in LV-MyoD transduced cells.BMC Musculoskeletal Disorders 2009, 10:51 http://www.biomedcentral.com/1471-2474/10/51
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have addressed the relative BMP-2 sensitivity of myoblasts
relative to fibroblasts and osteoprogenitors. We hypothe-
sized that myoblasts would show a strong osteogenic
response, particularly when compared to fibroblasts. Con-
sidering the pathological complications associated with
fibrosis in orthopaedic repair, the sensitivity of fibroblasts
to osteogenic stimulation is highly relevant.
Our data clearly confirms the body of literature showing
that BMP-2 treatment readily induces osteogenic differen-
tiation in myoblasts [15,16]. Consistent with prior stud-
ies, we observed an associated reduction in myogenic
markers in myoblasts undergoing osteogenesis [29]. Our
findings support our initial hypothesis that the osteogenic
potential of myoblasts when exposed to osteogenic sign-
aling is comparable to that of standard osteoprogenitors
and far exceeds that of fibroblasts. Finally, we speculated
that the sensitivity of cells to BMP-2 may reflect the
expression of BMPRs on the cell surface. Previous reports
have shown that BMPR-IA but not BMPR-1B is robustly
expressed in C2C12 myoblasts [32]. Transfection of a
dominant-negative BMPR-1A into BMP-2 treated C2C12
cells inhibited AP expression. This was partially rescued by
the transfection of wild-type BMPR-1A into C2C12 cells
over-expressing the truncated BMPR-1A mutant. In con-
trast, truncated BMPR-IB had no effect on BMP-2 signal-
ing in C2C12 cells. More recently, a siRNA knockdown of
BMPR-1A has been shown to inhibit BMP-2 mediated
osteogenic differentiation in human mesenchymal stem
cells [33].
We observed strong Bmpr-1a expression in myoblasts and
osteoprogenitors that could be enhanced by BMP-2 treat-
ment, while fibroblasts failed to express robust levels of
Bmpr-1a. In addition, fibroblasts transduced with the
myogenic transcription factor MyoD upregulated their
Bmpr-1a  expression. Although these data represent a
strong correlation between Bmpr-1a expression and BMP
sensitivity, the mechanism underlying the varying osteo-
genic potential of different cell lineages may be more
complex. Forced osteogenesis experiments using Runx2
expression constructs revealed that fibroblasts have a
reduced capacity for mineralization that is likely to be
independent of extracellular BMP signaling [38].
While we have observed a consistent upregulation of oste-
ogenic markers, our data does not fully resolve whether
genuine transdifferentiation has taken place. While myo-
genic cells treated with BMP-2 progressed from expressing
early differentiation markers (Ap/AP expression) to late
markers (Ocn expression, matrix mineralization), osteo-
genic stimulation was maintained during this time. When
Katagiri et al. treated C2C12 cells for 6 days with BMP-2
stimulation and then reverted to a myogenic growth
media, cells were found to revert to a myogenic profile
[15]. This would suggest that bone fide transdifferentiation
did not occur, and that muscle progenitors retained a
"memory" of their original myogenic lineage. However, it
is unclear if cells are treated with BMP for longer, whether
a myogenic memory would remain. Moreover, it is possi-
ble that returning cells to a myogenic media preferentially
selected for the adherence, survival, and proliferation of
cells that had not yet committed to an osteogenic status.
Finally, the myogenic reversion of BMP-2 treated cells in
vitro poorly models the in vivo situation where a muscle
progenitor may become exposed to persistent osteogenic
signals in a bone environment.
Although our results suggest that muscle progenitors have
a high responsiveness to BMP signaling, it does not rule
out the possibility that alternative cell populations may
contribute to bone formation in muscle. This includes cir-
culating osteoprogenitors originating from the bone com-
partment, as irradiation of the bone marrow
compartment can attenuate ectopic bone formation [39].
However, irradiation of progenitors in the soft tissues was
found to be equally effective, suggesting that local progen-
itor cells are also of importance [40]. Vascular mesoan-
gioblasts and pericytes have been a focus of recent interest
due to their potential for muscle cell therapy [41]. While
mesoangioblasts are of an endothelial lineage, pericytes
have been shown to not express vascular markers [42,43].
Although pericytes have been recently shown to be a sub-
population of progenitors with significant myogenic
potential, they do not express MyoD when freshly isolated
[42]. Thus between multi-lineage progenitor cells such as
mesoangioblasts, side-population cells and muscle-
derived stem cells, pericytes, and classical satellite cells,
the milieu of progenitor cells found in muscle tissue is
complex and ever expanding. The relative capacity of
these different subpopulations of myogenic progenitors
to respond to osteogenic stimulation has yet to be
explored, however we hypothesize that assaying for BMPR
expression will be an effective predictive measure. Based
on the presence of multiple myogenic-responsive ele-
ments in the Bmpr-1a/BMPR-1A promoter sequences, we
anticipate that all of these cell types will robustly express
Bmpr-1a.
There remains a possibility that other related receptors
may also be involved. In the genetic disease FOP, the
ectopic ossification of soft tissues in patients is the result
of a dominant mutation in ACVR1/ALK2, a type 1 BMP
receptor [44]. Based on molecular modeling, it was
hypothesized that this mutation led to destabilization of
a region used for binding negative regulators of R-Smad
signaling; thus the mutant receptor may be promiscuously
activated. Nevertheless, there are no other indications that
ACVR1/ALK2 has a normal physiological role in osteo-
genesis outside of the pathology of FOP. It has also beenBMC Musculoskeletal Disorders 2009, 10:51 http://www.biomedcentral.com/1471-2474/10/51
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recently demonstrated that BMP-6 and BMP-7 primarily
signal via the ACVR1/ALK2 receptor, while BMP-2 and
BMP-4 favor the BMPR-1A receptor [45].
Conclusion
In conclusion, this study characterizes the osteogenic dif-
ferentiation profile of committed osteoprogenitors, myo-
genic cells, and non-myogenic mesenchymal cells both
with and without BMP-2 treatment. Consistent with pre-
vious reports, myogenic cells readily establish an osteob-
lastic phenotype and we found this to be concomitant
with an upregulation of BMPR expression. Future work
will be required to explore whether endogenous myogenic
cells are capable of making an in vivo contribution to bone
formation in situations of ectopic bone formation and
bone repair.
We also observed distinct patterns of Bmpr-1a expression
in response to osteogenic stimulation, which may have
physiological significance. Bmpr-1a  levels also strongly
correlated with responsiveness to BMP-2, and thus Bmpr-
1a expression may be an alternative indicator for a cell's
osteogenic potential. This could have practical applica-
tions for the bone tissue engineering field where research-
ers are looking to isolate highly osteogenic cell
populations.
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